Home » News and press

NEWS AND PRESS

SmartTrak market analysis highlights Reapplix strong clinical data

SmartTRAK, the leading provider of market data and analysis for the wound and regenerative medicine markets, recently reported on current trends and the focus on differentiation in the wound care space. The report noted that Biologics is garnering attention through data and stated that “Autologous solutions for hard-to-heal wounds are gaining attention.

read more

Reapplix strengthens its Board of Directors and adds experienced profiles

Reapplix has elected additional board members to support and accelerate the company’s development. The newly elected board members bring substantial international competencies and comprehensive experience within business development, commercialisation, funding, operational excellence, financial management, auditing, risk management and corporate governance.

read more

3C PATCH® WILL BE THE NEW NAME FOR LEUCOPATCH® IN 2019

Based on the positive clinical results documented in the outcome data (recently published in The Lancet Diabetes & Endocrinology) of a major international randomized controlled trial of our LeucoPatch® wound healing technology, Reapplix’s primary focus now shifts from development to commercialization.

read more

PRESS RELEASE: Positive outcome data of large Randomized Controlled Trial presented at American Diabetes Association Scientific Sessions & Reapplix business update

Reapplix ApS, the regenerative medicine company, initially focussed on chronic wounds, announces that positive outcome data of an independent Randomized Controlled Trial (RCT) of its LeucoPatch® wound healing platform was presented at the American Diabetes Association 78th Scientific Sessions meeting in Orlando, Florida. The Company has also provided an update on the Company’s progress.

read more

SmartTrak market analysis highlights Reapplix strong clinical data

SmartTRAK, the leading provider of market data and analysis for the wound and regenerative medicine markets, recently reported on current trends and the focus on differentiation in the wound care space. The report noted that Biologics is garnering attention through data and stated that “Autologous solutions for hard-to-heal wounds are gaining attention.

read more

Reapplix strengthens its Board of Directors and adds experienced profiles

Reapplix has elected additional board members to support and accelerate the company’s development. The newly elected board members bring substantial international competencies and comprehensive experience within business development, commercialisation, funding, operational excellence, financial management, auditing, risk management and corporate governance.

read more

3C PATCH® WILL BE THE NEW NAME FOR LEUCOPATCH® IN 2019

Based on the positive clinical results documented in the outcome data (recently published in The Lancet Diabetes & Endocrinology) of a major international randomized controlled trial of our LeucoPatch® wound healing technology, Reapplix’s primary focus now shifts from development to commercialization.

read more

Dr. Magnus Löndahl presented Clinical experiences with LeucoPatch and the status of the large RCT at the Innovations in Wound Healing meeting.

MD, PhD Magnus Löndahl one of 4 principal investigators of the large randomized controlled trial of LeucoPatch/3C Patch on diabetic foot ulcers presented “Clinical experiences with LeucoPatch and status of the large RCT: Leucopatch™ System in the Management of Hard-To-Heal Diabetic Foot Ulcers” at the 4th annual Innovations in Wound Healing meeting December 9th 2017 in Bimini, Bahamas.

read more

Key patents granted in Europe and Eurasia

Reapplix ApS, developers of the unique LeucoPatch active wound therapy, have today announced that they have received notification that key patents have been granted in Europe and in Eurasia.

read more

Patent news – Patent granted in Japan

Reapplix ApS, developers of the unique LeucoPatch active wound therapy, have today announced that they have received notification that a key patent has been granted in the Japan.

read more

PRESS RELEASE: Positive outcome data of large Randomized Controlled Trial presented at American Diabetes Association Scientific Sessions & Reapplix business update

Reapplix ApS, the regenerative medicine company, initially focussed on chronic wounds, announces that positive outcome data of an independent Randomized Controlled Trial (RCT) of its LeucoPatch® wound healing platform was presented at the American Diabetes Association 78th Scientific Sessions meeting in Orlando, Florida. The Company has also provided an update on the Company’s progress.

read more

PRESS RELEASE: Reapplix confirms new funds raised

Reapplix today announced that it has successfully closed a new funding round of €2.7 million. This new funding was provided by the existing investors, SEED Capital Denmark, Novo Seeds and Vækstfonden (The Danish Growth Fund).

read more